Strategic Industry Insight: Decoding the FDA Warning Letter to Respilon Production S.R.O. and the Path to Regulatory Recovery

1. Strategic Context and the Compliance Imperative

At Persimmon Engineering (台南梁山工程顧問有限公司), we recognize that the FDA’s regulatory posture has shifted from traditional site inspections toward a high-frequency, document-centric oversight model. The recent Warning Letter issued to Respilon Production S.R.O. is a landmark example of the FDA leveraging its authority under Section 704(a)(4) of the FD&C Act to conduct remote records reviews. For manufacturers in Tainan and across the broader international market, this case serves as a "proxy warning": the FDA no longer needs to step foot on your factory floor to halt your exports. A Warning Letter of this magnitude is a call to move beyond mere "check-box" compliance and fundamentally elevate Quality Management Systems (QMS) to meet Current Good Manufacturing Practice (CGMP) standards. The FDA’s explicit demand for a "Qualified Consultant" under 21 CFR 211.34 underscores that internal remediation is no longer viewed as sufficient once systemic failures are exposed. From a strategic perspective, external expertise is now a "defense of the license." A consultant does not merely provide technical oversight; they serve as a third-party certifier to the Agency, providing the objective evidence required to restore regulatory trust and maintain US market access. The following forensic breakdown of the Respilon case details the technical failures that led to this crisis and the methodology required for a successful recovery.

2. Forensic Analysis of CGMP Violations in the Respilon Case

The FDA’s enforcement actions center on the "Identity, Strength, Quality, and Purity" (ISQP) framework. When a manufacturer fails to scientifically prove these attributes, the Agency legally classifies the product as "adulterated" under Section 501(a)(2)(B). This status renders the product unmarketable and exposes the firm to severe legal liability.

Technical Breakdown of Non-Compliance Findings

Regulatory Citation	Nature of Violation	The "So What?" Layer (Strategic Impact)
21 CFR 211.84(d)(1) & (2)	Failure to conduct identity testing on each component; failure to validate supplier reliability.	Product Integrity Risk: Without container-level testing, raw materials are unverified. This can lead to catastrophic contamination, necessitating a full market withdrawal.
21 CFR 211.166(a)	Absence of a written stability testing program to support labeled expiration dates.	Inventory Invalidation: Lack of stability data invalidates the entire inventory currently in the U.S. market, typically triggering a voluntary recall to mitigate safety risks.
21 CFR 211.100(a)	Failure to establish adequate process controls or validate manufacturing reproducibility.	Legal Fiction: A process that is not validated is "legally out of control." Consequently, Batch Production Records are viewed by auditors as unreliable documentation rather than proof of quality.
21 CFR 211.165(e)	Failure to validate the accuracy, sensitivity, and specificity of test methods.	Scientific Invalidity: If the analytical method for an active ingredient is unverified, all release data is scientifically unsound. The FDA assumes the product's quality is unknown.
21 CFR 211.194(a)	Incomplete laboratory records; Certificates of Analysis (COA) omitted raw assay data.	Data Integrity Failure: The omission of raw data is a fundamental breach of transparency. Without contemporaneous, complete records, the firm's entire quality system is deemed compromised.

Immediate Red Flags Identified:

• Lethal Impurity Oversight: The firm failed to perform USP identification tests for components at high risk for contamination with Diethylene Glycol (DEG) or Ethylene Glycol (EG). These are the primary drivers of current FDA 704(a)(4) scrutiny due to their history of causing mass poisoning events.
• Assumptions vs. Empirical Data: The firm claimed microbial proliferation was "not possible" based on water activity being "less than (b)(4)." The FDA rejected this because the claim was based on assumptions rather than a comprehensive microbial risk assessment or validated stability data.
• Methodological Inadequacy: Utilizing analytical methods for active ingredients that lacked demonstrated specificity or robustness, essentially making "Pass" results on a COA meaningless.

3. Evaluative Impact: Commercial Risks and Market Barriers

An FDA Warning Letter is a public indictment that disrupts the global supply chain. For Respilon, the consequences are immediate and punitive, serving as a cautionary tale for any firm neglecting the technical requirements of the US market.

The Consequences of Non-Compliance:

Operational Disruption:

• Withholding of Approvals: The FDA may stop approving any new drug applications (ANDAs/NDAs) or supplements listing the Brno facility until compliance is verified.
• Mandatory Re-inspection: Compliance status is only restored after a successful follow-up inspection, a process that can take months or years.

Legal/Financial Liability:

• Section 801(a)(3) Import Detention: Products are likely to be detained at the border without physical examination ("DWPE"), effectively ending the firm’s US revenue stream.
• Erosion of Trust: A Certificate of Analysis (COA) that only states "PASSED" without providing raw assay data is viewed as a "transparency gap." This lack of data integrity causes the FDA to lose all confidence in the firm's Laboratory Control System.

4. The 15-Day Rapid Response Framework: Persimmon Engineering’s Methodology

The 15-working-day window following a Warning Letter is the most critical period in a firm's history. Persimmon Engineering utilizes this window to pivot a manufacturer from a state of crisis to a state of remediation through a high-intensity protocol.

Regulatory Recovery Roadmap:

• Immediate Gap Analysis & Retrospective Review: We lead an investigation into the root causes of the citations. Crucially, we initiate a Retrospective Review of all batches currently in distribution within the U.S. that are within their labeled shelf life to assess the need for immediate safety actions.
• Consultant Integration & Certification: Per 21 CFR 211.34, Persimmon Engineering serves as the lead technical expert. We do not just consult; we certify the remediation efforts to the FDA, acting as the primary interlocutor with the Office of Manufacturing Quality.
• Strategic CAPA Implementation: We develop a comprehensive Corrective and Preventive Action (CAPA) plan. For complex remediations, we establish a rigorous "schedule for completion" with milestones that demonstrate continuous progress to the Agency.
• The Six-System Audit: The FDA mandates a comprehensive audit of the firm's entire operation. In the Respilon case, the Laboratory Control System and the Quality System are the primary points of failure. Persimmon Engineering focuses on fortifying these core systems, knowing that failures here inevitably cascade into the Production, Materials, Facilities, and Packaging systems.

5. Potential Risk Solutions and Future-Proofing Compliance

Transitioning to proactive "quality-by-design" is the only way to avoid the cycle of Warning Letters. Persimmon Engineering implements three Strategic Remediation Pillars:

• Pillar 1: Robust Component Qualification: We mandate identity testing for every container of each lot unless a rigorous, validated supplier reliability program is in place (21 CFR 211.84). This specifically includes screening for high-risk impurities like DEG and EG.
• Pillar 2: Life-Cycle Process Validation: We implement Process Performance Qualification (PPQ) protocols. Validation is treated as a continuous life cycle, utilizing intensive monitoring to characterize intra-batch variation and ensure a consistent "state of control."
• Pillar 3: Scientific Integrity in Laboratory Controls: We oversee the Verification of Compendial Methods (USP <1226>) or full validation of proprietary methods. We ensure that every analytical result is supported by raw assay data, adhering to strict data integrity standards where "complete and contemporaneous" is the absolute baseline.

6. Conclusion: The Persimmon Engineering Partnership

Persimmon Engineering (台南梁山工程顧問有限公司) provides the bridge between Tainan-based manufacturing excellence and the stringent requirements of the global FDA landscape. The Respilon case demonstrates that the FDA is uncompromising regarding technical oversights and data integrity. Regulatory compliance is not a hurdle to be cleared; it is the fundamental foundation for sustainable global market growth. When facing the threat of market exclusion, the only path forward is immediate, expert-led action. Persimmon Engineering stands ready to defend your license, remediate your systems, and ensure your facility represents the gold standard of pharmaceutical quality.

Warning Letter 320-26-69

April 20, 2026

Dear Mr. Zima:

Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our May 2, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Respilon Production S.R.O, FEI 3018892481, at Prikop 843/4, Brno, Jihomoravsky, Czech Republic.

This Warning Letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations, parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).

Following our review of records and other information you provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including but not limited to, the following:

1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).

Your response to our request for records under section 704(a)(4) indicated that you do not test the identity of each incoming component used in the manufacture of your drug products, such as (b)(4), before manufacturing. In addition, you failed to test each shipment of (b)(4) for (b)(4) contamination before use. Identity testing for (b)(4) and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of (b)(4). Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacturing of your drug product. See FDA’s guidance document (b)(4) for help in meeting the CGMP requirements when manufacturing drugs containing ingredients at high risk for (b)(4) contamination.

2. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).

Your response to our request for records under section 704(a)(4) indicated that you have not performed stability studies for the OTC drug products you manufacture, despite your drug product’s displaying an expiration date on the label. Without the appropriate stability studies, you do not have scientific evidence to support whether your drug product’s active ingredient maintains its strength, purity, and quality throughout the shelf life of the product.

3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).

Your response to our request for records under section 704(a)(4) indicated that you failed to adequately validate your drug manufacturing processes to demonstrate that they are reproducible and controlled. Process validation evaluates the soundness of design and the state of control of a process throughout its life cycle. Each significant stage of a manufacturing process must be designed appropriately and must ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and to evaluate batches to determine whether an initial state of control has been established.

4. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).

Your response to our request for records under section 704(a)(4) indicated that you failed to adequately validate the test method used to analyze raw materials and finished drug products. Method validation or verification has not been completed for the active ingredient assay testing for (b)(4). Your analytical method does not demonstrate specificity, accuracy, precision, and robustness. Additionally, it appears that your firm is not performing microbiological testing for each batch of your drug products before release. In your response, you state that your drug product has low (b)(4) at less than (b)(4) and that microbial proliferation is not possible. However, you have not validated your overall manufacturing process or conducted stability studies to determine if microbial contamination proliferates throughout the shelf life of the product. You have not provided a comprehensive microbial risk assessment of your manufacturing steps, such as in-process hold times, storage conditions, and the microbial load of your (b)(4) ingredients. The statement in your response that you intend to conduct reduced microbial testing is insufficient, based on the limited information you provided and the lack of documentation to support your approach.

5. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (211.194(a)).

Your response to our request for records under section 704(a)(4) indicated that your finished drug product’s Certificate of Analysis did not provide an individual test result for (b)(4) content. The “Batch Production” record that you provided as your Certificate of Analysis states “PASSED” in the “Conformity” section but does not provide an assay result.

CGMP Consultant Recommended

Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.

Conclusion

The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations. Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Respilon Production S.R.O., Prikop 843/4, Brno, Jihomoravsky, Czech Republic into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).

This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018892481 and ATTN: Erika V. Butler.

Sincerely,
/S/
Francis Godwin
Director
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research